{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"36.4","value":"1.8"},{"groupId":"OG001","lowerLimit":"0.2","upperLimit":"35.9","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Event-free survival is the time from the first day of treatment until any treatment failure (lack of response within 6 cycles of treatment, relapse, or death).","dispersionType":"Full Range","groups":[{"description":"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nTrametinib: Given PO\n\nVenetoclax: Given PO","id":"OG000","title":"Cohort A (Newly Diagnosed AML Patients)"},{"description":"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nTrametinib: Given PO\n\nVenetoclax: Given PO","id":"OG001","title":"Cohort B (Relapsed/Refractory AML or Higher-risk MDS or CMML Patients)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the first day of treatment until any treatment failure (lack of response within 6 cycles of treatment, relapse, or death), assessed until study completion","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}